Plain-English translation of NCT06514534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing asciminib, an oral medication taken twice daily, for people with chronic myeloid leukemia (a blood cancer) who have a specific genetic change called T315I and have not benefited from or cannot take other available treatments. Researchers want to see if this medication can be effective and safe for this particular group of patients. The study will run for a core phase focused on results, followed by an extension phase where participants can continue the medication if it's working.
Many people with this type of blood cancer and this specific genetic mutation run out of effective treatment options because they don't respond to or can't tolerate existing medications. This trial is looking for a new option for those patients.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice each day at a dose of 200 mg, which may be adjusted up to 400 mg total daily based on how you respond and tolerate it. The trial involves visits to the research center where doctors will monitor your blood counts, check for side effects, and measure how well the medication is working. After the core study phase, if the medication is helping you, you may be able to continue taking it in an extension phase until it becomes commercially available or the company makes other decisions about the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
France